Efficacy and Safety of Subclinical Sensitization with Diphenylcyclopropenone in Children with Alopecia Areata: A Retrospective Study
- Author:
Sang-Hoon LEE
1
;
Chung Hyeok LEE
;
Hyun KANG
;
Won-Soo LEE
Author Information
1. Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
- Publication Type:Original Article
- From:Korean Journal of Dermatology
2022;60(6):371-377
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Contact immunotherapy with diphenylcyclopropenone is one of the first-line treatments for extensive alopecia areata, despite its adverse effects (AEs).
Objective:This study aimed to investigate whether a modified contact immunotherapy treatment protocol can safely promote hair regrowth in children.
Methods:Children with alopecia areata who were treated with modified contact immunotherapy with diphenylcyclopropenone were retrospectively reviewed. All patients were sensitized with 0.1% diphenylcyclopropenone and began treatment at subsequent increasing concentrations. The efficacy, AEs, and demographic factors were evaluated.
Results:A total of 32 patients, aged 9 to 17 years (mean age, 14.6 years), were included in the study. The mean disease duration was 26.8 months. Ten (31.3%) and 11 patients (34.4%) showed complete and partial responses, respectively. No AEs were observed after the sensitization. During treatment, 13 patients (40.6%) did not experience any AEs. Sixteen patients (50.0%) showed mild to moderate pruritus, and only three patients (9.4%) had severe pruritus. However, all AEs were well controlled.
Conclusion:A modified diphenylcyclopropenone treatment protocol with subclinical sensitization could induce a favorable therapeutic response and fewer AEs in children.
